1. Volume 385, Issue 9984, Pages 2272-2279 (June 2015)
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double- blind, placebo-controlled, phase 1 trial 
Feng-Cai Zhu, MSc, Li-Hua Hou, PhD, Jing-Xin Li, MSc, Shi-Po Wu, PhD, Prof Pei Liu, PhD, Gui-Rong Zhang, PhD, Yue-Mei Hu, BSc, Fan-Yue Meng, MSc, Jun-Jie Xu, PhD, Rong Tang, MSc, Jin-Long Zhang, PhD, Wen-Juan Wang, MSc, Lei Duan, MSc, Kai Chu, MSc, Qi Liang, MSc, Jia-Lei Hu, MSc, Li Luo, MSc, Tao Zhu, PhD, Jun-Zhi Wang, PhD, Dr Wei Chen, PhD 
The Lancet 
Volume 385, Issue 9984, Pages (June 2015)
DOI: /S (15)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2
Glycoprotein-specific T-cell response in all participants (A) and in those with pre-existing adenovirus type-5 neutralising antibody titres ≤1:200 (B) or >1:200 (C)
IFN=interferon. PBMC=peripheral blood mononuclear cells.
The Lancet  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Figure 3 CD4 and CD8 T-cell response
CD4 T-cell response in all participants (A) and those with pre-existing adenovirus type-5 neutralising antibody titres ≤1:200 (B) or >1:200 (C), and CD8 T-cell response in all participants (D) and those with pre-existing adenovirus type-5 antibody titres ≤1:200 (E) or >1:200 (F).
The Lancet  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions